3,302.40
+4.20%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Gland Pharma
Its shares trade on NSE under the ticker GLAND.NS. It has been listed since 20 November 2020. In the fiscal year to 31 March 2026, it reported revenue of ₹64.31bn and net income of ₹10.27bn. At that date it held total assets of ₹125.11bn and shareholders' equity of ₹103.58bn.
Gland Pharma Ltd. manufactures pharmaceutical ingredients and injectable formulations. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2020-11-20. The firm specializes in complex injectables and is engaged in the sterile injectables, oncology, and ophthalmology segments. The firm provides contract development, own development, dossier preparation and filing, technology transfer and manufacturing across a variety of delivery systems. Its products are available in liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. Its key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Blood Related, Cardiac, Gastrointestinal, Gynaecological, Hormones, Neuro / Cns, Ophthal / Otologicals, Pain/Analgesics, Respiratory and Vitamins / Minerals / Nutrients. Its products are sold across various countries, which include United States, Europe, Canada, and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 20 Nov 2020
- Employees
- 4,585
- Website
- glandpharma.com ↗
Leadership
Pay as last reported
- Mr. Srinivas SaduExecutive Chairman of the Board, since 2011₹62.3m
- Mr. Shyamakant GiriChief Executive Officer
- Mr. Ravi MitraChief Financial Officer₹20.4m
- Mr. Sampath PallerlamudiCompliance Officer, Company Secretary, since 2020₹6.0m
- Ms. Wei HuangNon-Executive Director
- Dr. Jia Ai ZhangNon-Executive Director
- Mr. Wenjie ZhangNon-Executive Director
- Mr. Satyanarayana ChavaliNon-Executive Independent Director₹4.4m
- Ms. Naina KidwaiNon-Executive Independent Director₹11.0m
- Mr. Essaji VahanvatiNon-Executive Independent Director₹3.9m
- Mr. Udo VetterNon-Executive Independent Director₹4.1m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 58
- Environment
- 48
- Social
- 59
- Governance
- 67
- Direct emissions (scope 1)
- 15,736 t
- Energy emissions (scope 2)
- 81,154 t
- Women in the workforce
- 13%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Gland Pharma Ltd. specializes in complex injectables and sterile formulations for oncology and ophthalmology segments.
- The company employs 4,585 full-time employees and offers contract development and manufacturing services.
- Its products include Heparin Sodium Injection and Enoxaparin Sodium Injection for anti-infective and anti-neoplastics categories.
Weaknesses
- The company's business is concentrated in the Health Care sector with limited diversification into other industries.
- Gland Pharma Ltd. has no presence in the Financials or Real Estate sectors.
- Its product portfolio focuses on injectables without significant expansion into oral or topical formulations.
Opportunities
- The United States and Europe represent key markets for Gland Pharma's injectable products.
- Gland Pharma can expand its contract development services to include new delivery systems like patches or implants.
- The growing demand for oncology treatments presents an opportunity for increased market share.
Threats
- The company faces competition from established players in the United States pharmaceutical market.
- Gland Pharma Ltd. operates in a highly regulated industry with strict compliance requirements.
- European regulatory changes could impact the approval process for new injectable formulations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.